Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYM0UY)

• Drug Name: ORY-2001 Drug Info
• Synonyms: Vafidemstat; 1357362-02-7; ORY-2001; Vafidemstat [INN]; LZ82JLT4UP; UNII-LZ82JLT4UP; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; (1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; SCHEMBL528204; CHEMBL4802155; XBBRLCXCBCZIOI-DLBZAZTESA-N; BCP29383; BDBM50594947; AKOS040742807; MS-25100; HY-112623; CS-0058593; ORY 2001; ORY-2001; ORY2001; A930244; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 66714983
  TTD Drug ID: DMYM0UY

Molecule-Related Drug Atlas

Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[3]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[3]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[4]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[5]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[6]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[7]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[8]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[9]
Tarnylcypromine derivative 3	DMKJOMC	N. A.	N. A.	Patented	[9]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[10]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[11]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[12]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[13]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[14]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[15]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[16]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[17]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[18]
Budipine	DMODHQI	Migraine	8A80	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysine-specific histone demethylase 1 (LSD)	TTNR0UQ	KDM1A_HUMAN	Inhibitor	[2]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03867253) A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
• [5] Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
• [6] A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
• [7] Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
• [8] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [9] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [10] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [11] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [12] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [14] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [15] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [16] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [17] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [19] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.